Abstract
Background: Crohn's disease (CD) is an autoimmune disease of the gastrointestinal tract, characterized by relapsing and remitting courses. The disease is debilitating in nature with three prominent phenotypic clinical presentations; fistulizing, stenosing, and inflammatory. Stem cells offer new hope for CD patients by modifying the immune response and progression of the healing process.
Aim: This mini-review discusses the role of stem cells in treating CD, their effectiveness as a new therapy and their current limitations.
Methods: The author conducted a literature review on recent randomized controlled trials and cohort studies concerned with the topic in question using the following keywords (Crohn's Disease, perianal fistula, Stem cell therapy, mesenchymal stem cells, remission).
Results: Clinical trials show that the stem cells are more effective in the CD-associated complex perianal fistula than the CD enteritis. At present, there are no standardized guidelines regarding dose of stem cells used, number of doses administered, route of administration, type of stem cells used. Only one group of researchers proposed a standardized procedure for injecting mesenchymal stem cells in complex perianal fistula, according to their own experience in clinical trials. Moreover, mesenchymal stem cells and their related types (placental, adipose tissue, umbilical tissue, etc.) are the safest and effective in clinical trials. Currently, the commercially available mesenchymal stem cells preparation (Darvadstrocel (Cx601)) is the only one approved by The United States Food and Drug Administration (FDA) for clinical use in refractory CD associated complex perianal fistula.
Conclusion: Stem cell therapy (SCT) shows promise in inducing remission in refractory Crohn's colitis, and perianal fistula, but further research is required before SCT could be applied to clinical practice guidelines.
Keywords: Crohn's disease, stem cell therapy, mesenchymal, hematopoietic, perianal fistula, inflammatory bowel disease.
[1]
Cooper J, Blake I, Lindsay JO, Hawkey CJ. Living with Crohn’s disease: An exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study). BMJ Open 2017; 7(9): e015201.
[http://dx.doi.org/10.1136/bmjopen-2016-015201] [PMID: 28893742]
[http://dx.doi.org/10.1136/bmjopen-2016-015201] [PMID: 28893742]
[2]
Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: A patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis 2014; 20(3): 545-52.
[http://dx.doi.org/10.1097/01.MIB.0000440983.86659.81] [PMID: 24407484]
[http://dx.doi.org/10.1097/01.MIB.0000440983.86659.81] [PMID: 24407484]
[3]
El‐Nakeep S, Abdel Latif O, Shawky A, Nabhan AF. Stem cell transplantation for induction of remission in medically refractory Crohn’s disease. Cochrane Database Syst Rev 2018; 2018(7): CD013070.
[http://dx.doi.org/10.1002/14651858.CD013070]
[http://dx.doi.org/10.1002/14651858.CD013070]
[4]
Lightner AL, Faubion WA. Mesenchymal stem cell injections for the treatment of perianal Crohn’s disease: What we have accomplished and what we still need to do. J Crohn’s Colitis 2017; 11(10): 1267-76.
[http://dx.doi.org/10.1093/ecco-jcc/jjx046] [PMID: 28387832]
[http://dx.doi.org/10.1093/ecco-jcc/jjx046] [PMID: 28387832]
[5]
Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn’s fistula: A meta-analysis and systematic review. Stem Cell Res Ther 2021; 12(1): 32.
[http://dx.doi.org/10.1186/s13287-020-02095-7] [PMID: 33413661]
[http://dx.doi.org/10.1186/s13287-020-02095-7] [PMID: 33413661]
[6]
Qiu Y, Li MY, Feng T, et al. Systematic review with meta-analysis: The efficacy and safety of stem cell therapy for Crohn’s disease. Stem Cell Res Ther 2017; 8(1): 136.
[http://dx.doi.org/10.1186/s13287-017-0570-x] [PMID: 28583202]
[http://dx.doi.org/10.1186/s13287-017-0570-x] [PMID: 28583202]
[7]
Hall NJ, Rubin GP, Dougall A, Hungin AP, Neely J. The fight for ‘health-related normality’: A qualitative study of the experiences of individuals living with established inflammatory bowel disease (ibd). J Health Psychol 2005; 10(3): 443-55.
[http://dx.doi.org/10.1177/1359105305051433] [PMID: 15857873]
[http://dx.doi.org/10.1177/1359105305051433] [PMID: 15857873]
[8]
Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: A randomized clinical trial. JAMA 2015; 314(23): 2524-34.
[http://dx.doi.org/10.1001/jama.2015.16700] [PMID: 26670970]
[http://dx.doi.org/10.1001/jama.2015.16700] [PMID: 26670970]
[9]
Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology 2015; 149(4): 918-27.e6.
[http://dx.doi.org/10.1053/j.gastro.2015.06.014] [PMID: 26116801]
[http://dx.doi.org/10.1053/j.gastro.2015.06.014] [PMID: 26116801]
[10]
Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 2011; 60(6): 788-98.
[http://dx.doi.org/10.1136/gut.2010.214841] [PMID: 21257987]
[http://dx.doi.org/10.1136/gut.2010.214841] [PMID: 21257987]
[11]
Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: A randomized controlled clinical trial. Gut Liver 2018; 12(1): 73-8.
[http://dx.doi.org/10.5009/gnl17035] [PMID: 28873511]
[http://dx.doi.org/10.5009/gnl17035] [PMID: 28873511]
[12]
Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63(1): 1-12.
[http://dx.doi.org/10.1002/bjs.1800630102] [PMID: 1267867]
[http://dx.doi.org/10.1002/bjs.1800630102] [PMID: 1267867]
[13]
Litta F, Parello A, Ferri L, et al. Simple fistula-in-ano: Is it all simple? A systematic review. Tech Coloproctol 2021; 25(4): 385-99.
[http://dx.doi.org/10.1007/s10151-020-02385-5] [PMID: 33387100]
[http://dx.doi.org/10.1007/s10151-020-02385-5] [PMID: 33387100]
[14]
Scott LJ. Darvadstrocel: A review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs 2018; 32(6): 627-34.
[http://dx.doi.org/10.1007/s40259-018-0311-4] [PMID: 30298387]
[http://dx.doi.org/10.1007/s40259-018-0311-4] [PMID: 30298387]
[15]
Ruiz MA, Kaiser Junior RL, Piron-Ruiz L, Peña-Arciniegas T, Saran PS, De Quadros LG. Hematopoietic stem cell transplantation for Crohn’s disease: Gaps, doubts and perspectives. World J Stem Cells 2018; 10(10): 134-7.
[http://dx.doi.org/10.4252/wjsc.v10.i10.134] [PMID: 30397423]
[http://dx.doi.org/10.4252/wjsc.v10.i10.134] [PMID: 30397423]
[16]
Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Sénéjoux A, Vitton V. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology 2010; 138(7): 2275-81.
[http://dx.doi.org/10.1053/j.gastro.2010.02.013]
[http://dx.doi.org/10.1053/j.gastro.2010.02.013]
[17]
Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009; 52(1): 79-86.
[http://dx.doi.org/10.1007/DCR.0b013e3181973487] [PMID: 19273960]
[http://dx.doi.org/10.1007/DCR.0b013e3181973487] [PMID: 19273960]
[18]
Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. Lancet 2016; 388(10051): 1281-90.
[http://dx.doi.org/10.1016/S0140-6736(16)31203-X] [PMID: 27477896]
[http://dx.doi.org/10.1016/S0140-6736(16)31203-X] [PMID: 27477896]
[19]
Molendijk I, van der Meulen-de Jong AE, Verspaget HW, et al. Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn’s disease. Eur J Gastroenterol Hepatol 2018; 30(10): 1148-54.
[http://dx.doi.org/10.1097/MEG.0000000000001208] [PMID: 30095479]
[http://dx.doi.org/10.1097/MEG.0000000000001208] [PMID: 30095479]
[20]
O’Riordan JM, Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with Crohn’s and non-Crohn’s related fistula-in-ano. Dis Colon Rectum 2012; 55(3): 351-8.
[http://dx.doi.org/10.1097/DCR.0b013e318239d1e4] [PMID: 22469804]
[http://dx.doi.org/10.1097/DCR.0b013e318239d1e4] [PMID: 22469804]
[21]
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110(10): 3499-506.
[http://dx.doi.org/10.1182/blood-2007-02-069716] [PMID: 17664353]
[http://dx.doi.org/10.1182/blood-2007-02-069716] [PMID: 17664353]
[22]
Saleh M, Taher M, Sohrabpour AA, et al. Perspective of placenta derived mesenchymal stem cells in acute liver failure. Cell Biosci 2020; 10(1): 71.
[http://dx.doi.org/10.1186/s13578-020-00433-z] [PMID: 32483484]
[http://dx.doi.org/10.1186/s13578-020-00433-z] [PMID: 32483484]
[23]
Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016; 18(3): 123-30.
[http://dx.doi.org/10.1016/j.tgie.2016.08.001] [PMID: 28458507]
[http://dx.doi.org/10.1016/j.tgie.2016.08.001] [PMID: 28458507]
[24]
Cantarelli BCF, de Oliveira RS, Alves AMA, Ribeiro BJ, Velloni F, D’Ippolito G. Evaluating inflammatory activity in Crohn’s disease by cross-sectional imaging techniques. Radiol Bras 2020; 53(1): 38-46.
[http://dx.doi.org/10.1590/0100-3984.2018.0096] [PMID: 32313336]
[http://dx.doi.org/10.1590/0100-3984.2018.0096] [PMID: 32313336]
[25]
Goran L, Negreanu AM, Stemate A, Negreanu L. Capsule endoscopy: Current status and role in Crohn’s disease. World J Gastrointest Endosc 2018; 10(9): 184-92.
[http://dx.doi.org/10.4253/wjge.v10.i9.184] [PMID: 30283601]
[http://dx.doi.org/10.4253/wjge.v10.i9.184] [PMID: 30283601]
[26]
García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48(7): 1416-23.
[http://dx.doi.org/10.1007/s10350-005-0052-6] [PMID: 15933795]
[http://dx.doi.org/10.1007/s10350-005-0052-6] [PMID: 15933795]
[27]
Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006; 12(4): 304-10.
[http://dx.doi.org/10.1097/01.MIB.0000215091.77492.2a] [PMID: 16633052]
[http://dx.doi.org/10.1097/01.MIB.0000215091.77492.2a] [PMID: 16633052]
[28]
Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: Current and future directions. Clin Gastroenterol Hepatol 2016; 14(3): 348-354.e17.
[http://dx.doi.org/10.1016/j.cgh.2015.06.001] [PMID: 26071941]
[http://dx.doi.org/10.1016/j.cgh.2015.06.001] [PMID: 26071941]
[29]
Norton C, Czuber-Dochan W, Bassett P, et al. Assessing fatigue in inflammatory bowel disease: Comparison of three fatigue scales. Aliment Pharmacol Ther 2015; 42(2): 203-11.
[http://dx.doi.org/10.1111/apt.13255] [PMID: 25989464]
[http://dx.doi.org/10.1111/apt.13255] [PMID: 25989464]
[30]
Kaptchuk TJ. Intentional ignorance: A history of blind assessment and placebo controls in medicine. Bull Hist Med 1998; 72(3): 389-433.
[http://dx.doi.org/10.1353/bhm.1998.0159] [PMID: 9780448]
[http://dx.doi.org/10.1353/bhm.1998.0159] [PMID: 9780448]
[31]
Moustgaard H, Clayton GL, Jones HE, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: Meta-epidemiological study. BMJ 2020; 368: l6802.
[http://dx.doi.org/10.1136/bmj.l6802] [PMID: 31964641]
[http://dx.doi.org/10.1136/bmj.l6802] [PMID: 31964641]
[32]
Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: Comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010; 16(12): 2131-6.
[http://dx.doi.org/10.1002/ibd.21300] [PMID: 20848462]
[http://dx.doi.org/10.1002/ibd.21300] [PMID: 20848462]
[33]
Novak G, Parker CE, Pai RK, et al. Histologic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst Rev 2017; 7: CD012351.
[http://dx.doi.org/10.1002/14651858.CD012351.pub2] [PMID: 28731502]
[http://dx.doi.org/10.1002/14651858.CD012351.pub2] [PMID: 28731502]
[34]
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006; 55(3): 426-31.
[http://dx.doi.org/10.1136/gut.2005.069476] [PMID: 16474109]
[http://dx.doi.org/10.1136/gut.2005.069476] [PMID: 16474109]
[35]
Thavorn K, van Katwyk S, Krahn M, et al. Value of mesenchymal stem cell therapy for patients with septic shock: An early health economic evaluation. Int J Technol Assess Health Care 2020; 36(5): 525-32.
[http://dx.doi.org/10.1017/S0266462320000781] [PMID: 33059782]
[http://dx.doi.org/10.1017/S0266462320000781] [PMID: 33059782]
[36]
Bislenghi G, Wolthuis A, Van Assche G, Vermeire S, Ferrante M, D’Hoore A. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease. Expert Opin Biol Ther 2019; 19(7): 607-16.
[http://dx.doi.org/10.1080/14712598.2019.1623876] [PMID: 31121104]
[http://dx.doi.org/10.1080/14712598.2019.1623876] [PMID: 31121104]
[37]
NCPE. National Centre for Pharmacoeconomics. 2019. Cost-effectiveness of darvadstrocel (Alofisel®) for treatment of complex perianal fistulae in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulae have shown an inadequate response to at least one conventional or biologic therapy Darvadstrocel should be used only after conditioning of the fistulas. Available from: http://www.ncpe.ie/wp-content/uploads/2018/07/Summary-Darvadstrocel-23.09.2019.pdf
[38]
Qiu X, Feng JR, Chen LP, et al. Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn’s disease: A systematic review and meta-analysis. Medicine 2017; 96(26): e7381.
[http://dx.doi.org/10.1097/MD.0000000000007381] [PMID: 28658168]
[http://dx.doi.org/10.1097/MD.0000000000007381] [PMID: 28658168]
[39]
Lightner AL. The present state and future direction of regenerative medicine for perianal Crohn’s disease. Gastroenterology 2019; 156(8): 2128-2130.e4.
[http://dx.doi.org/10.1053/j.gastro.2019.04.031] [PMID: 31034831]
[http://dx.doi.org/10.1053/j.gastro.2019.04.031] [PMID: 31034831]
[40]
Martin PA, Coveney C, Kraft A, Brown N, Bath P. Commercial development of stem cell technology: lessons from the past, strategies for the future. Regen Med 2006; 1(6): 801-7.
[http://dx.doi.org/10.2217/17460751.1.6.801] [PMID: 17465761]
[http://dx.doi.org/10.2217/17460751.1.6.801] [PMID: 17465761]
[41]
Daniel-Moreno A, Lamsfus-Calle A, Raju J, Antony JS, Handgretinger R, Mezger M. CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation. Bone Marrow Transplant 2019; 54(12): 1940-50.
[http://dx.doi.org/10.1038/s41409-019-0510-8] [PMID: 30903024]
[http://dx.doi.org/10.1038/s41409-019-0510-8] [PMID: 30903024]
[42]
Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012; 119(9): 1972-80.
[http://dx.doi.org/10.1182/blood-2011-11-354563] [PMID: 22210876]
[http://dx.doi.org/10.1182/blood-2011-11-354563] [PMID: 22210876]
[43]
Pellegrini G, Ardigò D, Milazzo G, et al. Navigating market authorization: The path holoclar took to become the first stem cell product approved in the European Union. Stem Cells Transl Med 2018; 7(1): 146-54.
[http://dx.doi.org/10.1002/sctm.17-0003] [PMID: 29280318]
[http://dx.doi.org/10.1002/sctm.17-0003] [PMID: 29280318]
[44]
Agency. EM. Orphan Maintenance Assessment Report. 2018 Alofisel (expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue): Treatment of anal fistula 2018. Available from: http://wwwemaeurop aeu/ (Accessed on: 23 feb 2021).
[45]
Mayer L, Pandak WM, Melmed GY, et al. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant Crohn’s disease: A phase 1 study. Inflamm Bowel Dis 2013; 19(4): 754-60.
[http://dx.doi.org/10.1097/MIB.0b013e31827f27df] [PMID: 23429460]
[http://dx.doi.org/10.1097/MIB.0b013e31827f27df] [PMID: 23429460]
[46]
Aghayan HR, Payab M, Mohamadi-Jahani F, Aghayan SS, Larijani B, Arjmand B. GMP-compliant production of human placenta-derived mesenchymal stem cells. Methods Mol Biol 2020; 2286: 213-25.
[http://dx.doi.org/10.1007/7651_2020_282]
[http://dx.doi.org/10.1007/7651_2020_282]
[47]
ATCC. Product Sheet: Primary bone marrow CD34+ cells, normal, human (ATCC® PCS800012™). American type culture collection. Available from: http://www.atcc.org
[48]
Samuel GN, Kerridge IH, O’Brien TA. Umbilical cord blood banking: Public good or private benefit? Med J Aust 2008; 188(9): 533-5.
[http://dx.doi.org/10.5694/j.1326-5377.2008.tb01769.x] [PMID: 18459926]
[http://dx.doi.org/10.5694/j.1326-5377.2008.tb01769.x] [PMID: 18459926]
[49]
Alexander T, Arnold R, Hiepe F, Radbruch A. Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases. Clin Exp Rheumatol 2016; 34(4 Suppl. 98): 53-7.
[PMID: 27586805]
[PMID: 27586805]
[50]
Kosaric N, Kiwanuka H, Gurtner GC. Stem cell therapies for wound healing. Expert Opin Biol Ther 2019; 19(6): 575-85.
[http://dx.doi.org/10.1080/14712598.2019.1596257] [PMID: 30900481]
[http://dx.doi.org/10.1080/14712598.2019.1596257] [PMID: 30900481]
[51]
Carvello M, Lightner A, Yamamoto T, Kotze PG, Spinelli A. Mesenchymal stem cells for perianal Crohn’s disease. Cells 2019; 8(7): 764.
[http://dx.doi.org/10.3390/cells8070764] [PMID: 31340546]
[http://dx.doi.org/10.3390/cells8070764] [PMID: 31340546]
[52]
Lee CK, Melmed GY. Multidisciplinary team-based approaches to IBD management: How might “one-stop shopping” work for complex IBD Care? Am J Gastroenterol 2017; 112(6): 825-7.
[53]
Slonim-Nevo V, Sarid O, Friger M, et al. Effect of social support on psychological distress and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis 2018; 24(7): 1389-400.
[http://dx.doi.org/10.1093/ibd/izy041] [PMID: 29893949]
[http://dx.doi.org/10.1093/ibd/izy041] [PMID: 29893949]
[54]
Leshem RN. Inflammatory bowel disease support groups: A primer for gastroenterology nurses. Gastroenterol Nurs 2003; 26(6): 246-50.
[http://dx.doi.org/10.1097/00001610-200311000-00006] [PMID: 14676612]
[http://dx.doi.org/10.1097/00001610-200311000-00006] [PMID: 14676612]
Article Metrics
35
1